News about Biotechnology

Azenta Signs Definitive Agreement to Sell B Medical Systems to Thelema for USD 63 Million

Azenta, Inc., a leading provider of life sciences solutions worldwide, announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to Thelema S.À R.L., for a purchase price of USD 63 million. The transaction is expected to close on or before March 31, 2026.

Biotechnology | 30/12/2025 | By Darshana |  153

S&T Minister Dr Jitendra Singh inaugurates Biotechnology Research and Innovation Council (BRIC)

Union Minister of State (Independent Charge) for Science and Technology (S&T) Dr Jitendra Singh formally inaugurated the Biotechnology Research and Innovation Council (BRIC) Secretariat, on 29 December, by unveiling the inaugural curtain, marking the official opening of a new milestone in India’s biotechnology journey.

Biotechnology | 30/12/2025 | By Darshana |  103

GENESIS Pharma Secures Exclusive Rights to Commercialise Donidalorsen Across 14 CEE Markets

GENESIS Pharma, a regional biopharma company specialising in the commercialisation of innovative medicines in Central and Eastern Europe (CEE), has entered into an exclusive agreement with Otsuka Pharmaceutical Europe Ltd., the European arm of Otsuka Pharmaceutical Co., Ltd., for the distribution and commercialisation of donidalorsen.

Biotechnology | 16/12/2025 | By Darshana |  234

Vektor Medical Secures FDA Clearance for Next-Generation vMap Arrhythmia Mapping Technology

Vektor Medical, a San Diego–headquartered medical technology company focused on advancing arrhythmia diagnosis and treatment, has received US Food and Drug Administration 510(k) clearance for its next-generation vMap technology.

Biotechnology | 14/12/2025 | By Darshana |  313

Sentynl Appoints myTomorrows as Global Provider to Expand Managed Access Program

Sentynl Therapeutics, a biopharmaceutical company based in the USA and wholly owned by Zydus Lifesciences, has appointed myTomorrows as the global provider for its Managed Access Program (MAP).

Biotechnology | 11/12/2025 | By Darshana |  131

Zydus to Commercialise Keytruda Biosimilar FYB206 in US and Canada

Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada.

Biotechnology | 10/12/2025 | By Darshana |  177

Dr. Reddy's Signs USD 370 Million Licensing Deal for Eftilagimod Alfa

Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotechnology company Immutep to commercialise its investigational immunotherapy, Eftilagimod Alfa (Efti), across markets outside North America, Europe, Japan and Greater China.

Biotechnology | 09/12/2025 | By Darshana |  112

Rondo Therapeutics Begins First-in-Human Trial of Novel CD28 - Nectin-4 Bispecific for Solid Tumours

Rondo Therapeutics, a clinical-stage biopharmaceutical company developing next-generation T-cell engaging bispecific antibodies for solid tumours, has begun dosing patients in its phase 1/1b clinical trial of RNDO-564.

Biotechnology | 07/12/2025 | By Darshana |  233

Cytiva and Veeda Lifesciences Launch New HCP Services Centre

The collaboration between Cytiva and Veeda Lifesciences brings a dedicated Host Cell Protein (HCP) services centre offering comprehensive HCP coverage, characterization, and quantification assays, enabling global biopharma companies to enhance the safety, efficacy, and quality of their biologics development

Biotechnology | 28/11/2025 | By Dineshwori |  192

Teva secures EC approval for two denosumab biosimilars, Ponlimsi and Degevma

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has received marketing authorizations from the European Commission for its two denosumab biosimilars—Ponlimsi, referencing Prolia, and Degevma, referencing Xgeva.

Biotechnology | 27/11/2025 | By Darshana |  163